公开(公告)号：US11059780B2

公开(公告)日：2021-07-13

申请号：US16491811

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Daini ,  Yuhei Miyanohana ,  Satoshi Mikami ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: C07D207/12 ,  C07D405/12 ,  C07D403/12 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D403/14 ,  C07D493/08 ,  C07D487/10 ,  C07D498/10 ,  C07D471/04 ,  C07D413/12 ,  C07D491/107 ,  C07D487/08

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12077522B2

公开(公告)日：2024-09-03

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Kentaro Rikimaru ,  Yoshihiro Banno ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Yoshihide Tomata ,  Yuji Ishichi ,  Shogo Marui ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike

IPC: C07D401/14 ,  C07D211/56 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D211/56 ,  C07D405/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11028048B2

公开(公告)日：2021-06-08

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Marilena Pira ,  Javier Miguelez-Ramos

IPC: C07D207/14 ,  C07D407/08 ,  C07D417/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200247747A1

公开(公告)日：2020-08-06

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto

IPC: C07D207/14 ,  C07D417/06 ,  C07D407/08

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10428023B2

公开(公告)日：2019-10-01

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11440883B2

公开(公告)日：2022-09-13

申请号：US16811426

申请日：2020-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  C07D211/36 ,  C07D405/06 ,  A61P25/26 ,  C07D409/10 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11319286B2

公开(公告)日：2022-05-03

申请号：US16635408

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Yuichi Kajita ,  Satoshi Mikami ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Masaki Daini ,  Masaki Ogino ,  Kohei Takeuchi ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D207/14 ,  C07D401/14 ,  C07D403/06 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11034700B2

公开(公告)日：2021-06-15

申请号：US16491794

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Masaki Daini ,  Yuhei Miyanohana ,  Hideo Suzuki ,  Kenichiro Shimokawa ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: A61K31/40 ,  C07D491/107 ,  C07D207/12 ,  C07D207/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D409/06 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200207715A1

公开(公告)日：2020-07-02

申请号：US16811426

申请日：2020-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D417/14 ,  C07D417/06 ,  C07D413/06 ,  C07D405/12 ,  C07D405/10 ,  C07D403/06 ,  C07D401/14 ,  C07D401/10 ,  C07D401/06 ,  C07D207/14 ,  C07D205/04 ,  A61P25/00 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US09643957B2

公开(公告)日：2017-05-09

申请号：US14650429

申请日：2013-12-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Yuichi Kajita ,  Masato Yoshikawa ,  Shuhei Ikeda ,  Hiromi Fukuda

IPC: C07D403/12 ,  C07D471/08 ,  C07D491/08 ,  C07D213/12 ,  C07D498/08 ,  C07D405/12 ,  C07D401/14 ,  C07D417/14 ,  C07D451/04 ,  C07D487/10 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D401/12 ,  C07D239/42 ,  C07D413/04 ,  C07D417/04 ,  C07D451/02 ,  C07D487/18 ,  C07D491/18 ,  C07D403/04 ,  C07D403/14 ,  C07D471/10 ,  A61K9/20 ,  A61K9/48 ,  C07D213/72 ,  C07D487/08 ,  C12N9/99

CPC classification number: C07D498/08 ,  A61K9/2018 ,  A61K9/4858 ,  C07D213/12 ,  C07D213/72 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.